Metagenomi, Inc. Common Stock (MGX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 17 | 45 | 52 | 25 | 14 | 5 |
| Operating profit | $m | -96 | -101 | ||||||
| Net profit | $m | - | -21 | -44 | -68 | -78 | -88 | -93 | -90 |
| EPS reported | $ | -2.36 | -2.49 | ||||||
| Operating cashflow per share | $ | -2.39 | -2.27 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | -2.40 | -2.28 | ||||||
| Free cash flow | $m | -89 | -86 | ||||||
| Net debt | $m | -161 | -121 | ||||||
| Book value equity | $m | 159 | 113 | ||||||
| Book value per share | $ | 4.26 | 2.99 | ||||||
| Number of shares | m | 37.25 | 37.66 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.38 | 0.54 | ||||||
| P/S LTM | x | 2.39 | 4.45 | ||||||
| P/FCF LTM | x | -0.67 | -0.70 | ||||||
| EV/EBITDA LTM | x | -0.72 | -0.67 | ||||||
| EV/Sales LTM | x | 2.35 | 3.32 | ||||||
| Earnings Yield LTM | % | -1.46% | -2.02% | ||||||
| FCF Yield | % | -148.25% | -142.17% | ||||||
| Quality | |||||||||
| ROE | % | -55.40% | -63.65% | ||||||
| ROIC | % | -46.99% | -65.88% | ||||||
| Operating margin | % | -3.81% | -7.42% | ||||||
| Gross margin | % | +78.91% | +74.29% | ||||||
| FCF/Sales | % | -354.88% | -632.67% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -51.79% | -74.07% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.20 | -2.27 | ||||||
| Net Debt/EBITDA | x | 0.01 | 0.01 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +13.46% | ||||||
| Net debt/Equity | x | -1.01 | -1.07 | ||||||
| Gross debt/equity | x | 0.26 | 0.34 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Metagenomi, Inc. Common Stock (MGX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free